ArticleFrontiers in medicine2026
Enhancing the transduction efficiency of lentiviral vectors in CAR-T cell therapy through an optimization workflow.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Harnessing Vδ1Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Efficient lentiviral (LV) transduction is a cornerstone of CAR-T manufacturing, yet performance is often construct-specific and highly sensitive to production and delivery parameters. We developed a stepwise optimization workflow using an underperforming anti-FITC-CAR in Jurkat E6-1 cells and validated generalizability with a well-performing HER2 CAR (pHR_SFFv_4D5-WT-Highest), followed by translational testing in primary PBMCs. The strategy sequentially tuned LV concentration, brief agitation during transduction, packaging system, DNA input balance, and addition of a transduction enhancer, with outcomes quantified by flow cytometry (tdTomato and HA or c-myc tags). Concentrated supernatants and a short 2-h shaking step improved signal definition and yield; incorporating an alternative packaging plasmid and a modest DNA rebalance further increased performance. With a low-dose enhancer, Jurkat transduction with the anti-FITC-CAR arose from ∼1% to ∼40-50% tdTomato
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.